Macrogol En Electrolyten Teva (Sodium Hydrogen Carbonate, Potassium Chloride, Sodium Chloride, Macrogol 3350)

Macrogol 3350 acts as a large, non‑absorbable polymer that retains water in the intestinal lumen through osmotic activity. This increases stool water content, softens the stool, and stimulates peristalsis. The added electrolytes (sodium hydrogen carbonate, potassium chloride, sodium chloride) help preserve normal electrolyte concentrations during the laxation process.

The appropriate dose of Macrogol En Electrolyten Teva is determined by the prescribing healthcare professional based on the patient’s age, weight, severity of constipation, and the intended bowel‑preparation protocol. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for Macrogol En Electrolyten Teva in pregnancy and lactation are limited. The product should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision should be made by a qualified healthcare provider after evaluating the individual situation.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Compared with stimulant laxatives, macrogol‑based products act osmotically, offering a gentler, more predictable effect with fewer cramping sensations. Unlike saline laxatives, the added electrolytes help maintain fluid balance, making macrogol 3350 with electrolytes a preferred choice for bowel preparation when a controlled, isotonic environment is desired.

Macrogol En Electrolyten Teva should be stored at temperatures below 25 °C, in its original packaging, and protected from moisture. Keeping the product in a dry, cool place preserves its stability and ensures the electrolyte composition remains unchanged.

The product is taken orally, typically dissolved in a measured amount of water as directed by the prescriber. It should be consumed with adequate fluid intake to support the osmotic action and to help prevent dehydration, especially during bowel‑preparation regimens.

Serious risks include electrolyte imbalance (especially sodium or potassium disturbances), severe dehydration, and rare allergic reactions such as rash, angioedema, or anaphylaxis. Patients should be monitored for signs of these events, and the medication should be discontinued immediately if they occur.

Individuals with known hypersensitivity to macrogol or any of the electrolyte components should avoid this product. It is also contraindicated in patients with complete mechanical bowel obstruction, perforated gastrointestinal tract, or severe inflammatory bowel disease without medical supervision.